Buck Wealth Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Buck Wealth Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$169	Buy	+1	New	+$148	﹤0.01%	1101

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Buck Wealth Strategies's NBIX Position: Q2 2026 in Review

Buck Wealth Strategies opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1 share worth $169. The stake represents ﹤0.01% of the portfolio and ranks #1101 among its holdings.

420 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Buck Wealth Strategies held 1 share of Neurocrine Biosciences worth $169 as of Q2 2026.
Neurocrine Biosciences was a new Buck Wealth Strategies position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Buck Wealth Strategies's portfolio in Q2 2026, its #1101 holding.
420 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Buck Wealth Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.